People
There is something of a recurring theme among the life science, healthcare and biopharma industries: shortage of skilled employees will lead to a decrease in innovation.
Director Peter Marks said FY18 was productive and exciting as the FDA department continued to support the advancement of 21st century medicine.
Since GSK initiated this new focus, the company has made several key moves to support the plan, including the December 2018 acquisition of Tesaro Oncology.
The BioIT World Conference & Expo is going on in Boston, Massachusetts, highlighting companies and breakthroughs working on the data end of life sciences, whether that’s blockchain, artificial intelligence, machine learning, data science, deep learning or others.
Talaris, most recently known as Regenerex, will use the funding to launch a Phase III registration trial of its allogenic cell therapy in living donor kidney transplant recipients.
Research Fellow from German Research Center for Artificial Intelligence to lead team driving solutions for pharmaceutical partners
As Ned Sharpless takes over as acting commissioner of the U.S. Food and Drug Administration, he is not planning any disruptions or course corrections to the federal regulatory agency.
Janssen Pharmaceuticals presented data that showed its RNAi therapeutic candidate exhibited robust effects on the liver disease that takes the lives of more than 900,000 people annually.
The life science industry is continually making advancements in every area! We want to know what cool science innovations are currently in progress and the professionals behind them.
Stephen Quake, a Stanford University bioengineer and inventor, recently shared several years’ worth of email communications between himself and He with The New York Times.
PRESS RELEASES